Douglas M. McCarty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Douglas M. McCarty has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Haiyan Fu
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
10 shared publications Haiyan Fu
The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
5 shared publications- Marybeth Camboni
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, OH
5 shared publications - Aaron S. Meadows
Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, OH
4 shared publications - Christopher M. Walker
Center for Microbe and Immunity Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital
3 shared publications Julianne DiRosario
The Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
3 shared publications
Latest Publications
- 1 January 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 120 (1) , S47
Systemic gene transfer of scAAV9.U1a.hSGSH for MPS IIIA: tolerability and preliminary evidence for a biochemical effect
- 1 January 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 120 (1) , S47
Systemic gene transfer of scAAV9.U1a.hSGSH for MPS IIIA: tolerability and preliminary evidence for a biochemical effect
- 1 January 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 120 (1) , S48-S49
Global metabolomics profiling reveals profound metabolic impairments in patients with mucopolysaccharidosis type III
- 1 January 2017
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 120 (1) , S48-S49
Global metabolomics profiling reveals profound metabolic impairments in patients with mucopolysaccharidosis type III
- 1 December 2016
- Published by Elsevier in Current Opinion in Virology
- Vol. 21, 87-92
Crossing the blood–brain-barrier with viral vectors
- 1 December 2016
- Published by Elsevier in Current Opinion in Virology
- Vol. 21, 87-92
Crossing the blood–brain-barrier with viral vectors
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S276
698. Effective Depletion of Pre-Existing Anti-AAV Antibodies Requires Broad Immune Targeting
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S276
Open Access698. Effective Depletion of Pre-Existing Anti-AAV Antibodies Requires Broad Immune Targeting
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S47
Functional benefits of systemic rAAV9-hids gene delivery in MPS II mouse model
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S47
Functional benefits of systemic rAAV9-hids gene delivery in MPS II mouse model
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S79
Functional correction of mucopolysaccharidosis I in adult mice by a systemic rAAV9-IDUA gene delivery
- 1 February 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 117 (2) , S79
Functional correction of mucopolysaccharidosis I in adult mice by a systemic rAAV9-IDUA gene delivery
- Open Access
- 1 January 2016
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16036
Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery
- 1 January 2016
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 3, 16036
Open AccessFunctional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery
- 9 December 2015
- Published by SAGE Publications in Human Gene Therapy Clinical Development
A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB
No treatment is currently available for mucopolysaccharidosis (MPS) IIIB, a neuropathic lysosomal storage disease due to defect in α-N-acetylglucosaminidase (NAGLU). In preparation for a clinical trial, we performed an IND-enabling GLP-toxicology study to assess systemic rAAV9-CMV-hNAGLU gene delivery in WT C57BL/6 mice at 1x1014vg/kg and 2x1014vg/kg (n=30/group, M:F=1:1), and non-GLP testing in MPS IIIB mice at 2x1014vg/kg. Importantly, no adverse clinical signs or chronic toxicity were observed through the 6 month study duration. The rAAV9-mediated rNAGLU expression was rapid and persistent in virtually all tested CNS and somatic tissues. However, acute liver toxicity occurred in 33% (5/15) WT males in the 2x1014vg/kg cohort, which was dose-dependent, sex-associated and genotype-specific, likely due to hepatic rNAGLU over-expression. Interestingly, a significant dose response was observed only in the brain and spinal cord, whereas in the liver at 24-wk pi, NAGLU activity was reduced to endogenous levels in the high dose cohort but remained at supranormal levels in the low dose group. The possibility of rAAV9 germline transmission appears to be minimal. The vector delivery resulted in transient T-cell responses and characteristic acute antibody responses to both AAV9 and rNAGLU in all rAAV9-treated animals, with no detectable impacts on tissue transgene expression. This study demonstrates a generally safe and effective profile, and may have identified the upper dosing limit of rAAV9-CMV-hNAGLU via systemic delivery for the treatment of MPS IIIB.
- 9 December 2015
- Published by SAGE Publications in Human Gene Therapy Clinical Development
A GLP-compliant toxicology and biodistribution study: systemic delivery of a rAAV9 vector for the treatment of mucopolysaccharidosis IIIB
No treatment is currently available for mucopolysaccharidosis (MPS) IIIB, a neuropathic lysosomal storage disease due to defect in α-N-acetylglucosaminidase (NAGLU). In preparation for a clinical trial, we performed an IND-enabling GLP-toxicology study to assess systemic rAAV9-CMV-hNAGLU gene delivery in WT C57BL/6 mice at 1x1014vg/kg and 2x1014vg/kg (n=30/group, M:F=1:1), and non-GLP testing in MPS IIIB mice at 2x1014vg/kg. Importantly, no adverse clinical signs or chronic toxicity were observed through the 6 month study duration. The rAAV9-mediated rNAGLU expression was rapid and persistent in virtually all tested CNS and somatic tissues. However, acute liver toxicity occurred in 33% (5/15) WT males in the 2x1014vg/kg cohort, which was dose-dependent, sex-associated and genotype-specific, likely due to hepatic rNAGLU over-expression. Interestingly, a significant dose response was observed only in the brain and spinal cord, whereas in the liver at 24-wk pi, NAGLU activity was reduced to endogenous levels in the high dose cohort but remained at supranormal levels in the low dose group. The possibility of rAAV9 germline transmission appears to be minimal. The vector delivery resulted in transient T-cell responses and characteristic acute antibody responses to both AAV9 and rNAGLU in all rAAV9-treated animals, with no detectable impacts on tissue transgene expression. This study demonstrates a generally safe and effective profile, and may have identified the upper dosing limit of rAAV9-CMV-hNAGLU via systemic delivery for the treatment of MPS IIIB.
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S34
78. An IND-Enabling GLP-Toxicology and Biodistribution Study Assessing Systemic rAAV9-hNAGLU Gene Delivery for Treating MPS IIIB: Genotype- and Sex-Specific Dose-Limiting Acute Liver Toxicity in Male Wild Type C57BL/6 Mice
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S34
Open Access78. An IND-Enabling GLP-Toxicology and Biodistribution Study Assessing Systemic rAAV9-hNAGLU Gene Delivery for Treating MPS IIIB: Genotype- and Sex-Specific Dose-Limiting Acute Liver Toxicity in Male Wild Type C57BL/6 Mice
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S68
Improved brain expression of iduronate sulfatase in the MPS II mouse after intravenous delivery of a self-complimentary adeno-associated viral (AAV) vector
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S68
Improved brain expression of iduronate sulfatase in the MPS II mouse after intravenous delivery of a self-complimentary adeno-associated viral (AAV) vector